SPOTLIGHT: Karo Bio reorganizes

Sweden's Karo Bio has trimmed its staff by 14 workers, mostly in administration and R&D, as part of a shakeup aimed at cutting costs as it pushes its pipeline candidates along. Its lead therapy, KB2115 for dyslipidemia, is in Phase II clinical development. "We will focus on the programs where we have the best chance to deliver visible progress. Naturally, we regret that some of our loyal staff have to leave the company in connection with this process," says Per Olof Wallström, president of Karo Bio. Release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.